Critical Path Public Private Partnerships Clinical Trials Optional

Key Facts

Status: Open

Posted date: November 30, 2023

Opportunity ID: 351251

Opportunity number: FOR-FD-24-012

Opportunity category: Discretionary

Agency name: Food and Drug Administration

Agency code: HHS-FDA

Award floor: $20,000,000

Award ceiling: $20,000,000

Cost sharing required: No

Funding Instrument Types
  • Cooperative Agreement
  • Grant
Category of Funding Activity
  • Agriculture
  • Consumer Protection
  • Food and Nutrition
Eligible Applicants
  • Others
Tools
Categories (use these for quoted searches)
  • agency_code:hhs_fda
  • category_of_funding_activity:agriculture
  • category_of_funding_activity:consumer_protection
  • category_of_funding_activity:food_and_nutrition
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:others
  • funding_instrument_type:cooperative_agreement
  • funding_instrument_type:grant
  • opportunity_category:discretionary
  • status:open
Description

The FDA seeks an application to continue to maintain, manage existing consortia groups convened and established by the Critical Path Institute. This is a renewal of the cooperative agreement #5U18FD005320 as part of the Critical Path Initiative. This is in support of Critical Path Initiative introduced in Section 566 of the Federal Food, Drug, and Cosmetic Act. This includes developing innovative, collaborative projects in research, education, and outreach for fostering drug product innovation, enabling the acceleration of development, manufacturing, and translational therapeutics, enhancing safety, efficacy, quality, and performance. This funding opportunity will provide support, depending on availability of FDA funding.

Critical Path Public Private Partnerships Clinical Trials Optional
The FDA seeks an application to continue to maintain, manage existing consortia groups convened and established by the Critical Path Institute. This is a renewal of the cooperative agreement #5U18FD005320 as part of the Critical Path Initiative. This is in support of Critical Path Initiative introduced in Section 566 of the Federal Food, Drug, and Cosmetic Act. This includes developing innovative, collaborative projects in research, education, and outreach for fostering drug product innovation, enabling the acceleration of development, manufacturing, and translational therapeutics, enhancing safety, efficacy, quality, and performance. This funding opportunity will provide support, depending on availability of FDA funding.
Critical Path Public Private Partnerships Clinical Trials Optional
Open
Food and Drug Administration
Agriculture
Consumer Protection
Food and Nutrition
Cooperative Agreement
Grant
Others
2023-11-30